ROTEC – Inherited changes leading to altered levels of a blood protein, tissue factor pathway inhibitor and risk of cardiovascular disease
Dr William Astle
Institution or company
University of Cambridge
Haematology, Cardiovascular Disease
Tissue factor pathway inhibitor (TFPI) is a protein released into the blood stream by small blood cells called platelets and the cells lining blood vessels. TFPI provides a brake on the body’s clotting system such that if levels are increased this reduces the tendency of a person to form a blood clot. A recent large study in healthy volunteers showed that a common change in the DNA code (called a variant) affects the levels of TFPI. In our study, ROTEC, we will invite 20 participants from the NIHR BioResource to have a blood sample taken, which we will use to work out why these different TFPI levels occur in persons with and without the variant. We anticipate this research will help to identify potential new reasons for why some people are more prone to blood clots and cardiovascular diseases than others and help researchers find novel treatments for reducing the risk of conditions such as heart attacks and strokes.